(thirdQuint)A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Nave Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer.

 The objectives are to compare the efficacy, safety and immunogenicity of LY01008 and bevacizumab combined with paclitaxel and carboplatin for treatment of subjects with metastatic or recurrent nonsquamous non-small cell lung cancer.

 The subjects will receive the treatment with LY01008 or bevacizumab combined with paclitaxel and carboplatin for 4-6 cycles, and then both groups of subjects will receive the maintenance monotherapy with LY01008 until occurrence of progressive disease (PD), intolerable toxicity reaction, withdrawal of informed consent, loss to follow-up, death, conduct of other antineoplastic therapy or completion of the whole study.

 The doses of LY01008 and bevacizumab are 15 mg/kg in combination therapy.

 The dose of LY01008 in maintenance monotherapy is 15 mg/kg.

.

 A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Nave Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer@highlight

This is a Randomized, Double-blind, Multicenter Phase III Study Comparing Efficacy and Safety of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection) and Bevacizumab Combined with Paclitaxel and Carboplatin for Treatment of Naive Subjects with Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer